Bio-Rad Laboratories, Inc.’s Stock Price Drops to $281.02, Experiencing a 3.38% Decline: What’s Next for BIO?

Bio-Rad Laboratories, Inc. (BIO)

281.02 USD -9.84 (-3.38%) Volume: 0.37M

Bio-Rad Laboratories, Inc.’s stock price is currently at 281.02 USD, experiencing a drop of -3.38% this trading session, with a trading volume of 0.37M. With a year-to-date percentage change of -12.97%, Bio-Rad’s stock performance reflects the volatility of the market.

Latest developments on Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories (NYSE:BIO) is set to post Q1 2024 earnings on Tuesday, May 7, 2024, with a forecasted Q1 2025 earnings of $2.39 per share, according to Zacks Research. Despite a healthy balance sheet, the stock price gapped down to $290.86, with shareholders experiencing a 14% decline this week. The company’s recent collaboration with Oncocyte to commercialize transplant monitoring products and the commitment to purchase at $185, which earns an annualized 1.3% using options, have been key events leading up to today’s stock price movements.

Bio-Rad Laboratories, Inc. on Smartkarma

Analysts at Baptista Research have initiated coverage on Bio-Rad Laboratories A, a life science research and clinical diagnostic products manufacturer. In their first report, they highlight the company’s resilience and potential for growth in the coming years. Despite a slight decrease in net sales for FY 2023 compared to the previous year, Bio-Rad Laboratories shows promising signs of improvement.

Furthermore, Baptista Research‘s report delves into the impacts of China’s new policies and global economic conditions on Bio-Rad Laboratories. The analysis points out varying performances across segments and key issues such as the influence of Bio-pharma and challenges in the Chinese market. With these insights, investors can better understand the factors driving Bio-Rad Laboratories’ market dynamics.

A look at Bio-Rad Laboratories, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bio-Rad Laboratories A has a strong value score, indicating that the company is considered to be undervalued in the market. This suggests that investors may see potential for growth in the company’s stock price in the long term. However, the low dividend score may be a concern for income-seeking investors, as the company may not offer significant dividend payouts. In terms of growth, resilience, and momentum, Bio-Rad Laboratories A scores moderately, showing potential for steady growth and stability in the future.

Bio-Rad Laboratories, Inc. is a multinational company known for its diverse range of life science research products, clinical diagnostics, and analytical instrumentation. The company’s products are designed to separate and analyze complex chemical and biological materials, helping researchers and healthcare professionals identify, analyze, and purify components for various applications. With a strong value score and moderate scores in growth, resilience, and momentum, Bio-Rad Laboratories A seems poised for long-term success in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma